Who are L-BUPIVACAINE ; MORPHINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bupivacaine-fentanyl emergency group, bucain + fentanyl, Ropivacaine + Tramadol, Lidocaine 1% Injectable Solution, Sufentanil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l-bupivacaine-morphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

L-BUPIVACAINE ; MORPHINE — Competitive Intelligence Brief

L-BUPIVACAINE ; MORPHINE (L-BUPIVACAINE ; MORPHINE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid analgesic combination. Area: Anesthesia and Pain Management.

phase 3 Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine) Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

L-BUPIVACAINE ; MORPHINE (L-BUPIVACAINE ; MORPHINE) — Corporacion Parc Tauli. This combination uses L-bupivacaine (a local anesthetic) and morphine (an opioid analgesic) to provide regional anesthesia and postoperative pain relief through blockade of nerve conduction and opioid receptor activation.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
L-BUPIVACAINE ; MORPHINE TARGET	L-BUPIVACAINE ; MORPHINE	Corporacion Parc Tauli	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine)
Bupivacaine-fentanyl emergency group	Bupivacaine-fentanyl emergency group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Ropivacaine + Tramadol	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Lidocaine 1% Injectable Solution, Sufentanil	Lidocaine 1% Injectable Solution, Sufentanil	University of Saskatchewan	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid analgesic combination class)

Aga Khan University · 1 drug in this class
Conrad Arnfinn Bjørshol · 1 drug in this class
Corporacion Parc Tauli · 1 drug in this class
University of Debrecen · 1 drug in this class
University of Saskatchewan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-BUPIVACAINE ; MORPHINE — Competitive Intelligence Brief. https://druglandscape.com/ci/l-bupivacaine-morphine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab